MeSH tree: C20.683.515.761.480.150
In treating aggressive lymphomas and blood cancer (leukemia), chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken from patients and programmed by means of ...
Feb 9, 2024
0
82
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies. In work published ...
Feb 5, 2024
0
36
In a groundbreaking study, a team led by Würzburg Professor José Pedro Friedmann Angeli has shown that the cholesterol precursor 7-dehydrocholesterol (7-DHC) plays a crucial role as an antioxidant: it integrates into the ...
Jan 31, 2024
0
40
A study by researchers at Columbia and the Hong Kong University of Science and Technology is helping to clarify how low-grade lymphoma changes as it develops into a more aggressive tumor, which could lead to the development ...
Dec 18, 2023
0
62
Researchers have come one step closer to answering why, in some patients, a type of lymphoma changes from indolent to aggressive, and in particular, they are closer to identifying which patients are at high risk of this change ...
Dec 12, 2023
0
49
CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL), even for patients regarded as high risk due to comorbidities.
Dec 11, 2023
0
43
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a "surprisingly high" response ...
Dec 11, 2023
0
43
The Malaghan Institute of Medical Research, in collaboration with Wellington Zhaotai Therapies Limited, today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 chimeric antigen receptor ...
Dec 11, 2023
0
51
Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100% complete response (CR) rate at the higher dose levels studied in the trial, ...
Dec 11, 2023
0
39
For patients with diffuse large B-cell lymphoma (DLBCL), the chimeric antigen receptor T-cell therapies (CAR-T) axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are not cost-effective, according to ...
Dec 5, 2023
0
30
